5 completed, 1 withdrawn. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Withdrawn 1 |
Follow orteronel: new trials by email Literature Review of orteronel trials Research Report on orteronel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents Orteronel, Placebo - Prostate Cancer | Phase 3 | Withdrawn | Swiss Cancer Institute | 2014-08-19 | 2018-07-30 | |
| S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer TAK-700, Bicalutamide - Prostate Cancer | Phase 3 | Completed | SWOG Cancer Research Network | 1313 | 2013-03-08 | 2025-12-31 |
| Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy Orteronel, Placebo - Prostate Cancer | Phase 3 | Completed | Swiss Cancer Institute | 47 | 2012-09-01 | 2019-05-15 |
| Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer GnRH agonist, Anti-androgen, TAK-700 - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 239 | 2012-05-01 | 2026-03-06 |
| Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. Orteronel, Prednisone, Orteronel Placebo - Prostate Cancer | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 1099 | 2010-11-15 | 2018-12-19 |
| Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Orteronel, Placebo, Prednisone - Prostate Cancer | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 1560 | 2010-10-01 | 2017-05-17 |
Millennium Pharmaceuticals, Inc. (2) · Swiss Cancer Institute (2) · Radiation Therapy Oncology Group (1) · SWOG Cancer Research Network (1)
United States (4) · Canada (3) · Switzerland (3) · Australia (2) · Belgium (2) · Czechia (2) · Finland (2) · France (2) · Greece (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · Austria (1) · Belarus (1)
Richard Cathomas, MD (2) · Silke Gillessen, Prof (2) · M. Dror Michaelson, MD, PhD (1) · Neeraj Agarwal, M.D. (1)
PMID 26031410, PMID 29272162, PMID 25624429, PMID 25701170, PMID 27457964, PMID 35446628, PMID 37526936, PMID 38424319, PMID 38980676